Affordable Access

deepdyve-link
Publisher Website

Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use.

Authors
  • Baxter-Holland, Mia1
  • Dass, Crispin R1, 2
  • 1 School of Pharmacy and Biomedical Science, Curtin University, Perth, WA, Australia. , (Australia)
  • 2 Curtin Health Innovation Research Institute, Perth, WA, Australia. , (Australia)
Type
Published Article
Journal
The Journal of pharmacy and pharmacology
Publication Date
Mar 01, 2018
Volume
70
Issue
3
Pages
320–327
Identifiers
DOI: 10.1111/jphp.12869
PMID: 29355940
Source
Medline
Keywords
License
Unknown

Abstract

Doxorubicin-induced damage to MSCs is of concern clinically. However, MSCs also have been associated with resistance of tumour cells to drugs including doxorubicin. Further studies, particularly in vivo, are needed to provide consistent results of how the doxorubicin-induced changes to MSCs affect treatment and patient health.

Report this publication

Statistics

Seen <100 times